Clene’s cash, cash equivalents and marketable securities totaled $23.3 million as of December 31, 2022, compared to $50.3 million as of December 31, 2021. Clene expects that its resources as of December 31, 2022, will be sufficient to fund its operations into the third quarter of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLNN:
- Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights
- Clene price target raised to $8 from $6 at Cantor Fitzgerald
- Clene Gains on Promising Data in ALS
- Clene’s CNM-Au8 associated with delay in clinical worsening for ALS patients
- CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
